Timber Pharmaceuticals Discloses Communication From NYSE American
WARREN, NJ, July 03, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American:…
Pharmaceuticals, Biotechnology and Life Sciences
WARREN, NJ, July 03, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American:…
MOUNTAIN VIEW, Calif., July 03, 2023 (GLOBE NEWSWIRE) — IGM Biosciences, Inc. (NASDAQ: IGMS) today announced the closing of its…
Several elements are currently impacting our business and leading us today to revise our forecasts for the 2023 financial year.…
Nicox SA Société anonyme with a registered capital of € 50,170,498 Head Office: DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S.…
The FDA has granted orphan drug designation for IBT’s product IBP-1016 for gastroschisis. Infants suffering from gastroschisis suffer from risks…
CLEVELAND, July 03, 2023 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it has raised $25 million…
The 2nd edition of the eurekAWARDS is launched! Luxembourg, Belgium, Monaco, and Paris, France – 3 July 2023: eureKARE, a pioneering company…
YUSIMRY™ (adalimumab-aqvh) product image YUSIMRY™ (adalimumab-aqvh) – list price $995 per carton of two 40 mg/0.8 mL autoinjectorsSee https://www.yusimry.com for…
HTL’149 has been designed as a once-daily oral treatment to address positive and negative symptoms and cognitive impairment in schizophrenia…
Hyrimoz® (adalimumab-adaz) high-concentration formulation (HCF) biosimilar offers US patients reduced injection volume in citrate-free formulationAs one of the only adalimumab…